William Blair & Company
AXSM icon

William Blair & Company’s Axsome Therapeutics AXSM Stock Holding History

William Blair & Company’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74M Buy
23,450
+7,142
+44% +$1.55M 0.02% 493
2026
Q1 		$2.76M Sell
16,308
-30,532
-65% -$5.27M 0.01% 651
2025
Q4 		$8.55M Sell
46,840
-3,237
-6% -$452K 0.02% 392
2025
Q3 		$6.08M Buy
50,077
+595
+1% +$67K 0.02% 475
2025
Q2 		$5.17M Sell
49,482
-3,047
-6% -$323K 0.01% 486
2025
Q1 		$6.13M Sell
52,529
-1,853
-3% -$211K 0.02% 430
2024
Q4 		$4.6M Sell
54,382
-788
-1% -$72.5K 0.01% 516
2024
Q3 		$4.96M Sell
55,170
-3,981
-7% -$347K 0.01% 506
2024
Q2 		$4.76M Sell
59,151
-4,396
-7% -$325K 0.01% 502
2024
Q1 		$5.07M Buy
63,547
+55,027
+646% +$4.62M 0.02% 477
2023
Q4 		$678K Sell
8,520
-3,750
-31% -$251K ﹤0.01% 984
2023
Q3 		$858K Buy
12,270
+400
+3% +$29.9K ﹤0.01% 887
2023
Q2 		$853K Sell
11,870
-1,655
-12% -$122K ﹤0.01% 896
2023
Q1 		$834K Buy
13,525
+4,175
+45% +$274K ﹤0.01% 884
2022
Q4 		$721K Sell
9,350
-1,440
-13% -$86.1K ﹤0.01% 931
2022
Q3 		$481K Sell
10,790
-6,100
-36% -$305K ﹤0.01% 1051
2022
Q2 		$647K Buy
16,890
+1,703
+11% +$53.9K ﹤0.01% 984
2022
Q1 		$629K Sell
15,187
-900
-6% -$27.9K ﹤0.01% 1076
2021
Q4 		$608K Sell
16,087
-2,490
-13% -$91.6K ﹤0.01% 1141
2021
Q3 		$612K Buy
18,577
+10,050
+118% +$392K ﹤0.01% 1090
2021
Q2 		$575K Sell
8,527
-80
-0.9% -$4.8K ﹤0.01% 1107
2021
Q1 		$487K Sell
8,607
-7,660
-47% -$539K ﹤0.01% 1130
2020
Q4 		$1.32M Buy
16,267
+2,075
+15% +$155K ﹤0.01% 769
2020
Q3 		$1.01M Buy
14,192
+120
+0.9% +$9.35K ﹤0.01% 756
2020
Q2 		$1.16M Buy
14,072
+7,632
+119% +$587K 0.01% 689
2020
Q1 		$379K Sell
6,440
-11,292
-64% -$920K ﹤0.01% 951
2019
Q4 		$1.83M Buy
+17,732
New +$716K 0.01% 622

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

William Blair & Company's AXSM Position: Q2 2026 in Review

William Blair & Company increased its Axsome Therapeutics (AXSM) stake by 44% in Q2 2026, buying an estimated $1.55M and bringing the position to 23,450 shares worth $5.74M. The position accounts for 0.02% of the portfolio, ranked #493.

William Blair & Company first reported a position in AXSM in Q4 2019 and has held it in 27 quarters since. The position peaked at $8.55M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • William Blair & Company held 23,450 shares of Axsome Therapeutics worth $5.74M as of Q2 2026.
  • William Blair & Company bought 7,142 Axsome Therapeutics shares in Q2 2026, an estimated $1.55M.
  • Axsome Therapeutics made up 0.02% of William Blair & Company's portfolio in Q2 2026, its #493 holding.
  • William Blair & Company first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • William Blair & Company's Axsome Therapeutics position peaked at $8.55M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.